1. In Vivo
  2. >>Archive

In Vivo and In Vitro Diagnostics Converge: Siemens buys DPC

Why would imaging giant Siemens buy traditional in vitro diagnostics firm Diagnostic Products for $1.86 billion? Siemens has a mature imaging business, so the high growth opportunities in diagnostics, with their recurring revenue streams from consumables, look attractive. But more than that, it's becoming apparent that on the molecular level, in vivo imaging and in vitro diagnostics are converging.

Traditionally, diagnostic imaging and in vitro diagnostics have lived on different planets. In vivo imaging is a capital equipment business, while in vitro diagnostic businesses are built on reagents and consumables. Imaging looks for morphological changes in the body; invitro diagnostics detect analytes and markers of disease in tissues and fluids. Even the customers are different. Imaging equipment companies target radiologists, in vitro diagnostics companies sell to laboratories. So why would imaging giant Siemens AG announce, at the end of April, that it will acquire traditional in vitro diagnostics firm Diagnostic Products Corp. for $1.86 billion? [See Deal]

Siemens has a mature imaging business, so the high growth opportunities in diagnostics, with their recurring revenue streams from consumables,...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.